I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $311.05M

Company

Location

Date

Amt. (M)

Details


Biopsytec
Holding AG

Berlin

6/28

€5 (US$4.9)

Biopsytec raised more than US$4.9M in a second round of financing led by SAM Sustainability Private Equity LP; other investors were Deutsche Venture Capital and Industrie Management Holdings

Cellectis SA

Paris

6/25

€16 (US$15.7)

Cellectis completed a second round of financing, raising €16M (US$15.7M); investors included BankInvest BioMedical Venture, AGF Private Equity, funds managed by LCF Rothschild Asset Management, and Odyssee Venture

Centagenetix
Inc.

Cambridge, Mass.

6/17

Centagenetix received a $1.8M credit facility from the Technology and Life Sciences Division of Comerica Inc.

Enanta
Pharmaceuticals Inc.

Watertown, Mass.

6/13

$18

Enanta raised $18M in a Series E financing

Favrille Inc.

San Diego

6/11

$16.9

Favrille raised $16.9M in a financing led by Sanderling Ventures; other investors were De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Ltd., Forward Ventures and Alloy Ventures

FeRx Inc.

San Diego

6/6

$15

FeRx raised $15M in a private placement led by Johnson & Johnson Development Corp. and G.E. Capital's Capital Funding group; other investors were Elan International Services Ltd., Brentwood Associates VIII LP and California Technology Ventures LLC

Infinity
Pharmaceuticals
Inc.

Boston

6/24

$70

Infinity raised $70M in a Series B financing led by Advent Venture Partners; other investors were Venrock Associates, Prospect Venture Partners, Vulcan Ventures Inc., HBM Bioventure Ltd., Novartis Bioventure Fund, Wellcome Trust Ltd., Tallwood LP, Lotus BioScience Investment Holding, Alexandria Equities LLC, Stelios Papadopoulos, and two company founders; Three Crowns Capital served as placement agent

MacroGenics
Inc.

Rockville, Md.

6/6

$12.6

MacroGenics raised $12.6M in a financing led by InterWest Partners; other investors were MPM Capital, OrbiMed Advisors LLC, STARTech Early Ventures, Cogene Biotech Ventures, Hunt Ventures and Alexandria Realty Equities

Meristem Therapeutics

Clermont-Ferrand, France

6/27

€21.15 (US$20.7)

Meristem raised US$20.7M in a fourth financing round; investors were AGF Private Equity, Antin Innovation, CPR Private Equity, Innoven Parten- aires, La Compagnie Financiere de Rothschild, Odyssee Venture, Pechel Industries, SPEF, Banexi Ventures Partners, BNP Private Equity, Tethys, 3i, Sofimac and Sofipar

Odyssey Pharmaceuticals

San Ramon, Calif.

6/25

$15

Odyssey raised $15M in a Series B financing led by HBM Partners; other investors were Burrill & Co., HealthCap, Cogene Biotech and Incyte Genomics

Proteome
Sciences plc

Cobham, UK

6/12**

2.6 (US$3.8)

Proteome Sciences raised US$3.8M in an institutional placing

RxKinetix Inc.

Louisville, Colo.

6/21

$2.75

RxKinetix raised $2.75M in a private financing; investors were Aweida Ventures Management, MedVenture Associates and Elan Corp. plc

Salmedix Inc.

San Diego

6/20

$27.5

Salmedix raised $27.5M in a Series B financing; investors were CMEA Ventures Life Sciences, Delphi Ventures, Aberdare Ventures, BioFrontier Global Investments, GeneChem Therapeutics Venture Fund, ProQuest Investments, Ventures West, InterWest Partners, Versant Ventures and Alexandria Equities

Scynexis Inc.

Cambridge, UK

6/20

$29

Scynexis raised $29M in a private financing with U.S. and European venture funds; investors included Alta Partners, Burrill & Company, SR One, CDC Innovation Partners, KBL Healthcare Ventures, Genavent, SG Asset Management and Ventech

TopoTarget
A/S

Copenhagen, Denmark

6/12**

DKK120 (US$15.3)

TopoTarget raised US$15.3M in new funding, from HealthCap and BankInvest

XenoPort Inc.

Santa Clara, Calif.

6/3

$43.9

XenoPort raised $43.9M in a Series C financing led by HBM BioVentures AG; new investors were Lilly BioVentures, Lotus BioScience Ventures, Novartis BioVentures Ltd., and The Invus Group; repeat investors were Arch Venture Partners, CMEA Ventures, Frazier & Co., Lombard Odier & Cie, OrbiMed Advisors, Skyline Ventures and Venrock Associates

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $37.2M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Calcigen
Corp.*

Ben Franklin Technology Partners of Northeastern Pennsylvania

ND

Investment

Calcigen received the investment to com- mercialize Calcigen's non-mammalian bio- chemical production technology (6/24)

Celgene
Corp.
(CELG)

Novartis Pharma AG (Switzerland)

ND

Milestone payment

Celgene received an undisclosed milestone payment from Novartis for the selection of a selective estrogen receptor modulator preclinical candidate as part of the December 2000 osteoporosis collaboration (6/20)

Genmab A/S
(Denmark; CSE:GEN)

Hoffmann-La Roche Inc.

$20

Investment

Roche is investing $20M in Genmab as part of an agreement to expand a year-old deal to create and develop human antibody therapeutics (6/6)

Ligand Pharmaceuticals Inc. (LGND)

Eli Lilly and Co.

$1.1

Milestone payment

Ligand earned the $1.1M when Lilly's IND application for LY929 cleared its waiting period (6/5)

Nastech Pharmaceutical Co. Inc. (NSTK)

Pharmacia Corp.

$2

Milestone payment

Nastech received a $2M milestone payment under terms of their agreement for intra- nasally administered apomorphine for sexual dysfunction (6/5)

PG-TXL
Co. LP*

Cell Therapeutics Inc. (CTIC)

$1.5

Milestone payment

Cell Therapeutics made a $1.5M payment to PG-TXL following the completion of Phase II trial enrollment for Xyotax, as well as advan- cing Xyotax to Phase III trials (6/20)

Neurochem
Inc.
(Canada; TSE:NRM)

Picchio Pharma Inc. (Canada)

C$7 (US$4.5)

Investment

Picchio invested US$4.5M in Neurochem through the purchase of 2.8M units (6/19)

Texas
Biotechnology
Corp. (TXBI)

Schering-Plough Corp.

ND

Milestone payment

Texas Biotechnology received a milestone payment as part of an agreement to discover and develop VLA-4 antagonist drugs to treat asthma (6/19)

Transition Therapeutics Inc. (Canada; TSE:TTH)

Oncolytics Biotech Inc. (Canada)

C$4.8 (US$3.1)

Investment

Oncolytics acquired about 6.9M shares, or 15%, of Transition Therapeutics for US$3.1M (6/19)

Vernalis Group
plc
(UK; LSE:
VER)

Elan Corp. plc (Ireland)

$5

Milestone payment

Vernalis received a milestone payment of more than $5M from Elan for the launch of Frova for migraine in the U.S. (6/19)

Zycos Inc.*

Aventis Pasteur (France)

ND

Milestone payment

Zycos received a milestone payment for discovering antigenic information under a research collaboration initiated in 1999 (6/25)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed

CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange

No Comments